Swedish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Journal of the American Academy of Child and Adolescent Psychiatry 1995-Mar

Antidepressant prescription by British child psychiatrists: practice and safety issues.

Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Länken sparas på Urklipp
D J Bramble

Nyckelord

Abstrakt

OBJECTIVE

To evaluate the pattern of prescribing antidepressant (AD) drugs by British child psychiatrists with particular emphasis on the impact of newer-type (heterocyclic and selective serotonin reuptake inhibitor) agents on this practice and to assess the safety of AD use for children in terms of clinicians' reports of adverse effects.

METHODS

A short postal survey asking specific questions about these aspects of their clinical practice was sent to 350 British child psychiatrists.

RESULTS

The response rate was 71%. A clear majority of the 238 respondents (85%) who provided analyzable reports had prescribed ADs, the most popular of these being amitriptyline and imipramine, although nearly one third of prescribers also used newer agents occasionally and the selective serotonin reuptake inhibitors specifically, very rarely indeed. British child psychiatrists issued only one or two new prescriptions for AD medication per year. ADs were being used for a wide range of child and adolescent psychiatric disorders beyond the product data sheet-recommended indications of "depression" and "nocturnal enuresis." High rates of mostly mild adverse effects were reported in children treated with older-type ADs; however, the use of newer ADs did not appear to have influenced this picture when the reports of prescribers of only older ADs were compared with reports of those who also prescribed newer agents.

CONCLUSIONS

Despite a willingness to use this form of treatment, British child psychiatrists tend to use it very sparingly compared to practices revealed in American studies. The preferential and infrequent use of older AD agents may account for the high rates of adverse effects reported. These practices do not allow clinicians to become familiar with, and thus more comfortable about, using newer agents.

Gå med på vår
facebook-sida

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen

  • Fungerar på 55 språk
  • Växtbaserade botemedel som stöds av vetenskap
  • Örter igenkänning av bild
  • Interaktiv GPS-karta - märka örter på plats (kommer snart)
  • Läs vetenskapliga publikationer relaterade till din sökning
  • Sök efter medicinska örter efter deras effekter
  • Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent

Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning

Google Play badgeApp Store badge